Affiliated with uOttawa

REaCT
REthinking Clinical Trials

REaCT-5G

REaCT-5G

Type of G-CSF treatment (PEF vs FIL) during chemotherapy, impact on bone pain

Principal Investigator(s): Dr. Terry Ng

ClinicalTrials.gov: NCT04781959
Patients with early stage breast cancer who are being treated with chemotherapy also receive an injectable medication called granulocyte colony stimulating factor (G-CSF). G-CSF works by stimulating bone marrow to produce more immune cells to fight infection. Although G-CSF injections are effective at preventing infections, one of the most common side effects is bone pain. This multicenter, randomized clinical trial will compare bone pain experienced by patients after receiving either PEG or 5 days of FIL with adjuvant chemotherapy. This will be the first study to prospectively evaluate the patient-reported outcome of bone pain in this treatment comparison.

Sites: The Ottawa Hospital

Tags: Early stage Breast Cancer